Wire · opportunities
Common prescription drug delivers surprising results in hair-loss study
◆ Sectors
Medtech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Clinical trial results show upadacitinib (Rinvoq), a drug approved for inflammatory diseases, significantly promotes hair regrowth in patients with severe alopecia areata, offering a new treatment avenue under FDA review after EU approval.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Medtech founders working on hair loss should explore integrating or complementing JAK inhibitor treatments like Rinvoq now advancing in regulatory approval. Your path to market might open quicker with a drug already hitting strong clinical milestones for alopecia.
◆ Coverage
1 source · 24 Aug 2026
◆ Related on Wire
◆ Topics
Medtechalopecia-areatamedtechclinical-trialFDA-approvalJAK-inhibitor